Back to User profile » Dr Ennio Giulio Favalli
Papers published by Dr Ennio Giulio Favalli:
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
Biggioggero M, Crotti C, Becciolini A, Favalli EG
Drug Design, Development and Therapy 2019, 13:57-70
Published Date: 19 December 2018
Sarilumab: patient-reported outcomes in rheumatoid arthritis
Crotti C, Biggioggero M, Becciolini A, Favalli EG
Patient Related Outcome Measures 2018, 9:275-284
Published Date: 20 August 2018
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
Favalli EG, Becciolini A, Biggioggero M, Bertoldi I, Crotti C, Raimondo MG, Marchesoni A
Drug Design, Development and Therapy 2018, 12:1421-1429
Published Date: 24 May 2018
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
Becciolini A, Raimondo MG, Crotti C, Agape E, Biggioggero M, Favalli EG
Drug Design, Development and Therapy 2017, 11:1969-1978
Published Date: 28 June 2017
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG
Drug Design, Development and Therapy 2017, 11:1593-1603
Published Date: 24 May 2017
Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
Degli Esposti L, Favalli EG, Sangiorgi D, Di Turi R, Farina G, Gambera M, Ravasio R
ClinicoEconomics and Outcomes Research 2017, 9:9-17
Published Date: 21 December 2016